Stock Events

Stock Events

IMV 

$0.002000
24
+$0.00+0% Wednesday 13:30

Statistics

Day High
0.002
Day Low
0.002
52W High
0.01
52W Low
0.000001
Volume
-
Avg. Volume
-
Mkt Cap
16,686
P/E Ratio
-
Dividend Yield
18,732,087.44%
Dividend
374.64

Upcoming

29
SEP
Dividend Ex
 
29
SEP 27
Dividend Ex
Estimated
 

Dividends

18,732,087.44%Dividend Yield
Dec 25
$0.20
Dec 24
$0.14
Dec 23
$0.08
Dec 22
$0.07
Dec 21
$0.09
10Y Growth
15.67%
5Y Growth
24.57%
3Y Growth
35.72%
1Y Growth
N/A

Earnings

6AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
11.96
27.37
42.77
58.17
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-75.98MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMVIF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap18.82B
Moderna, Inc. is a competitor because it also focuses on mRNA technology for developing vaccines and therapeutics, similar to IMV's delivery platform for immunotherapies.
BioNTech
BNTX
Mkt Cap22.27B
BioNTech SE operates in the same space as IMV, developing and commercializing immunotherapies for cancer and other serious diseases, including mRNA-based vaccines.
Novavax
NVAX
Mkt Cap1.56B
Novavax, Inc. competes with IMV in the development of vaccines for infectious diseases, using its nanoparticle vaccine technology.
Pfizer
PFE
Mkt Cap148.41B
Pfizer Inc. is a broad-based competitor, involved in the development of vaccines and therapeutics, including its partnership with BioNTech on a COVID-19 vaccine, competing with IMV's infectious disease focus.
Johnson & Johnson
JNJ
Mkt Cap560.33B
Johnson & Johnson is involved in the research and development of vaccines and therapeutics for infectious diseases, making it a competitor in the same market as IMV.
Gilead Sciences
GILD
Mkt Cap160.36B
Gilead Sciences, Inc. competes with IMV in the development of therapeutics for infectious diseases and cancer, with a focus on antiviral drugs.
AMGEN
AMGN
Mkt Cap188.67B
Amgen Inc. competes in the biotechnology space, focusing on innovative therapeutics, including immunotherapies, which puts it in competition with IMV.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.62B
Regeneron Pharmaceuticals, Inc. is known for its development of monoclonal antibodies for the treatment of cancer and infectious diseases, competing with IMV's focus areas.
Novartis
NVS
Mkt Cap284.61B
Novartis AG competes with IMV in the development of novel healthcare solutions, including vaccines and cancer therapies, through its extensive research and development efforts.
Astrazeneca
AZN
Mkt Cap288.38B
AstraZeneca PLC competes in the development of vaccines and therapeutics for infectious diseases and cancer, overlapping with IMV's research and development focus.

About

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DPX platform, specifically engineered to attack cells expressing survivin. This compound is currently advancing through Phase II clinical studies for diffuse large B-cell lymphoma, ovarian cancer, and a variety of solid tumors including those affecting the bladder, liver, and MSI-H positive types. It is also in Phase I investigation for breast cancer. Additionally, the company's pipeline includes DPX-SurMAGE, undergoing Phase I clinical evaluation for bladder cancer, alongside the development of DPX-COVID-19 and DPX-RSV for addressing infectious diseases. The entity, previously known as Immunovaccine Inc., formally adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its corporate headquarters in Dartmouth, Canada.
Show more...
CEO
Mr. Andrew Hall M.Sc.
Employees
63
Country
Canada
ISIN
CA44974L3011

Listings

OTC Link
US
IMVIF
TSE
JP
7760.TSE

0 Comments

Share your thoughts

FAQ

What is IMV stock price today?▼
The current price of IMVIF is $0.00 USD — it has increased by +0% in the past 24 hours. Watch IMV stock price performance more closely on the chart.
What is IMV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IMV stocks are traded under the ticker IMVIF.
Is IMV stock price growing?▼
IMVIF stock has risen by +199,900.01% compared to the previous week, the month change is a +0% rise, over the last year IMV has showed a +1,900% increase.
What is IMV market cap?▼
Today IMV has the market capitalization of 16,686
When is the next IMV earnings date?▼
IMV is going to release the next earnings report on August 06, 2026.
What were IMV earnings last quarter?▼
IMVIF earnings for the last quarter are 0.37 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IMV revenue for the last year?▼
IMV revenue for the last year amounts to 0 USD.
What is IMV net income for the last year?▼
IMVIF net income for the last year is -75.98M USD.
How many employees does IMV have?▼
As of June 11, 2026, the company has 63 employees.
In which sector is IMV located?▼
IMV operates in the Other sector.
When did IMV complete a stock split?▼
The last stock split for IMV was on May 10, 2018 with a ratio of 1:3.2.
Where is IMV headquartered?▼
IMV is headquartered in Dartmouth, Canada.